Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: Results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era

Haematologica

Volumn 99, Issue 1, 2014, Pages 125-130

  Tadmor, Tamar ^a,b   Bari, Alessia ^c   Sacchi, Stefano ^c   Marcheselli, Luigi ^c   Liardo, Eliana Valentina ^c   Avivi, Irit ^b,d   Benyamini, Noam ^e   Attias, Dina ^a,b   Pozzi, Samantha ^c   Cox, Maria Christina ^e   Baldini, Luca ^f   Brugiatelli, Maura ^g   Federico, Massimo ^c   Polliack, Aaron ^h  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d RAMBAM MEDICAL CENTER   (Israel)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g Azienda Ospedaliera Papardo   (Italy)

^h HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MONOCYTES; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84892596915     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.088161     Document Type: Article

References (27)

1. [No authors listed] A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.
2. Project TN-HsLC. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89(11):3909-3918.
3. Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
4. Pfreundschuh M, Trümper L, Österborg A, Pettengell R, Trneny M, ImrieK, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7(5):379-391.
5. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with RCHOP. Blood. 2007;109(5):1857-1861.
6. Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G, et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell lymphoma. Leuk Lymphoma. 2008;49(9):1745-1751.
7. Marmey B, Boix C, Barbaroux JB, Dieu-Nosjean MC, Diebold J, Audouin J, et al. CD14 and CD169 expression in human lymphnodes and spleen: specific expansion of CD14 monocyte-derived cells in diffuse large B-cell lymphomas. Hum Pathol. 2006;37(1):68-77.
8. Tadmor T, Fell R, Polliack A, Attias D. Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lym-phoma-possible link with monocytic myeloid-derived suppressor cells. Hematol Oncol. 2012;(2):325-331.
9. Bari A, Tadmor T, Sacchi S, Marcheselli L, Liardo EV, Pozzi S, et al. Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas. Leuk Res. 2013;37(6):619-623.
10. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, et al. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leuk. 2013;13(1):15-18.
11. Li ZM, Huang J-J, Xia Y, Sun J, Huang Y, Wang Y, et al. Blood lymphocyte to-mono-cyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One. 2012;7(7):e41658.
12. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia. 2011;25(9):1502-1509.
13. Tadmor T, Benyamini N, Avivi I, Attias D, Polliack A. Absolute monocyte count is associated with adverse prognosis in diffuse large B-cell lymphoma: a validation study in a cohort of 219 patients from two centers. Haematologica. 2012;97(s1).318.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
15. Cox DR. Regression models and life tables. JR Stat Soc B. 1972;34:187-220.
16. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69:239-241.
17. Porrata L F, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica. 2012;97(2):262-269.
18. Porrata L F, Ristow K, Habermann TM, Witzig TE, Colgan J P, Inwards DJ, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lym-phoma. Br J Haematol. 2012;157(3):321-330.
19. Rambaldi A, Boschini C, Delaini F, Oldani E, Rossi A, Barbui AM, et al. The peripheral blood lymphocyte to monocyte ratio at diagnosis is a potent outcome predictor in diffuse large B-cell lymphoma treated with R-CHOP: a long-term analysis on 973 patients receiving chemotherapy with or without rituximab. Blood. 2012;120(21): Abstract 1553.
20. Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin lymphoma: correlation with tumor-associated macrophages. Oncologist. 2012;17(6):871-880.
21. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. Jama. 1982;247(18):2543-2546.
22. Newson R. Efficient calculation of jackknife confidence intervals for rankstatistics. J Statistical Software. 2006;15;1-10.
23. Castillo JJ, Morales D, Quinones P, Cotrina E, Desposorio C, Beltran B. Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma. 2010;51(10):1822-1828.
24. Mitrovic Z, Perry AM, Suzumiya J, Armitage JO, Au WY, Coiffier B, et al. The prognostic significance of lymphopenia in peripheral T-cell and natural killer/Tcell lym-phomas: a study of 826 cases from the international peripheral T-cell lymphoma project. Am J Hematol. 2012;87(8):790-794.
25. Hasenclever D, Diehl V, Armitage JO, Assouline D, Björkholm M, Brusamolino E, et al. A prognostic score for advanced Hodgkin's disease. N Engl J Med. 1998;339 (21):1506-1514.
26. Bari A, Marcheselli L, Sacchi S, Marcheselli R, Pozzi S, Ferri P, et al. Prognostic models for diffuse large B-cell lymphoma in the rit-uximab era: a never ending story. Ann Oncol. 2010;21(7):1486-1491.
27. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lym-phoma. N Engl J Med. 1993;328(14):1002-1006.